Clearpoint Neuro, INC

ClearPoint Neuro, Inc. held its annual stockholder meeting on May 20, 2026, where shareholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan and ratified the appointment of Cherry Bekaert LLP as auditors.

ClearPoint Neuro announced record full-year 2025 revenue of $37.0 million, up 18%, driven by strong organic growth and the IRRAS Holdings acquisition, with 2026 revenue projected between $52.0M and $56.0M.

ClearPoint Neuro, Inc. has filed an amendment to its 8-K, providing historical financial statements for the recently acquired IRRAS Holdings, Inc. and pro forma combined financial information.

ClearPoint Neuro announced preliminary unaudited fourth quarter 2025 revenue of $10.4 million, marking 20% comparable sales growth, and projected 2026 revenues between $54 million and $60 million.

ClearPoint Neuro, Inc. announced an internal reorganization of its Swedish subsidiary, IRRAS AB, to qualify it as an Immaterial Foreign Subsidiary under its Note Purchase Agreement.

ClearPoint Neuro, Inc. has finalized its acquisition of IRRAS Holdings, Inc., expanding its neurocritical care and drug delivery portfolio.

ClearPoint Neuro, Inc. reported an 18% increase in Q2 2026 revenue to $10.9 million, but also a significant widening of its net loss to $11.3 million, driven by increased operating expenses.

ClearPoint Neuro reports 43% revenue growth in Q1 2026, driven by IRRAS acquisition and expanded neurosurgical product sales.

ClearPoint Neuro, Inc. reported a 9% increase in total revenue for the third quarter of 2025, alongside an expanded net loss and the announcement of a strategic merger with IRRAS Holdings, Inc.

ClearPoint Neuro, Inc. reported a 17% increase in total revenue for Q2 2025, reaching $9.2 million, but saw its net loss widen by 32% to $5.8 million.

ClearPoint Neuro's Q1 2025 revenue increased by 11% year-over-year, driven by growth in neurosurgery navigation and biologics and drug delivery sectors, despite a net loss of $6.0 million.

ClearPoint Neuro saw a significant increase in product revenue during the third quarter of 2024, primarily driven by growth in its biologics and neurosurgery segments.

ClearPoint Neuro reports increased revenue and significant net losses in 2025, driven by the IRRAS acquisition and new debt financing, while advancing its neurosurgical and drug delivery platforms.

ClearPoint Neuro's 2024 10-K filing reveals revenue growth driven by neurosurgery and biologics, alongside reduced operating losses and strategic financial maneuvers.

ClearPoint Neuro's 10-K filing outlines the company's share structure, voting rights, and corporate governance policies, including anti-takeover provisions.

R. John Fletcher, a Director at ClearPoint Neuro, Inc., acquired 662 shares of common stock on July 1, 2026, as compensation for services rendered.

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., acquired 222 shares of common stock on July 1, 2026, as payment for services rendered.

ClearPoint Neuro CEO Joseph Burnett executed a Rule 10b5-1 trading plan, acquiring 20,000 shares and selling 20,000 shares.

ClearPoint Neuro, Inc. director Timothy T. Richards reported transactions involving the acquisition and disposition of company stock.

Director Matthew B. Klein reported a transaction involving the sale of 16,000 shares of ClearPoint Neuro, Inc. common stock.

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., acquired 12,820 restricted stock units on May 21, 2026, as detailed in a Form 4 filing.

ClearPoint Neuro, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 20, 2026, to elect directors, ratify auditors, and approve executive compensation and an incentive plan.

ClearPoint Neuro's proxy statement details the agenda for the annual stockholder meeting on May 21, 2025, including director elections and compensation plan approvals.

ClearPoint Neuro is holding its annual meeting on May 15, 2024, to vote on director elections, executive compensation, auditor ratification, and an amended incentive compensation plan.

ClearPoint Neuro, Inc. has filed an amendment to its Schedule 13G, detailing updated beneficial ownership information as of June 30, 2026.

MAK Capital Fund LP and associated entities have filed an amended Schedule 13G reporting a 6.3% beneficial ownership stake in ClearPoint Neuro, Inc.

Michael Bigger and associated investment entities have filed a Schedule 13G reporting a 7.54% beneficial ownership stake in ClearPoint Neuro, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in ClearPoint Neuro Inc. due to an internal organizational realignment.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 6.1% beneficial ownership stake in ClearPoint Neuro, Inc.

Michael Bigger and affiliated entities disclose a combined 7.8% beneficial ownership in ClearPoint Neuro, Inc. through a Schedule 13G Amendment.